Evaluating effect of teriflunomide on cortical atrophy in a subgroup analysis of patients defined by baseline MRI activity in the Phase 3 TOPIC study

被引：0
|
作者：
Zivadinov, R. [1 ]
Dwyer, M. G. [1 ]
Carl, E. [1 ]
Thangavelu, K. [2 ]
Cavalier, S. [2 ]
Bergsland, N. [1 ]
机构：
[1] Univ Buffalo, Buffalo, NY USA
[2] Sanofi Genzyme, Cambridge, MA USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2017年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PR2092
引用
收藏
页码：580 / 580
页数：1
相关论文
共 50 条
  • [1] Evaluating the Effect of Teriflunomide on Cortical Gray Matter Atrophy in the Phase 3 TOPIC Study
    Zivadinov, Robert
    Dwyer, Michael
    Carl, Ellen
    Thangavelu, Karthinathan
    Cavalier, Steven
    Bergsland, Niels
    NEUROLOGY, 2017, 88
  • [2] Evaluating the effect of teriflunomide on whole brain atrophy in the phase 3 TOPIC study
    Zivadinov, R.
    Dwyer, M. G.
    Carl, E.
    Thangavelu, K.
    Cavalier, S.
    Bergsland, N.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 463 - 463
  • [3] Effect of teriflunomide on MRI activity in patients with early MS: outcomes from the phase 3 TOPIC study
    Wolinsky, J. S.
    Comi, G.
    Kappos, L.
    Bauer, D.
    Truffinet, P.
    Miller, A. E.
    JOURNAL OF NEUROLOGY, 2014, 261 : S75 - S75
  • [4] Effect of teriflunomide on MRI activity in patients with early MS: outcomes from the phase 3 TOPIC study
    Wolinsky, J. S.
    Comi, G.
    Kappos, L.
    Bauer, D.
    Truffinet, P.
    Miller, A. E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 103 - 103
  • [5] MRI outcomes in patients with early multiple sclerosis treated with teriflunomide: subgroup analyses from the TOPIC phase 3 study
    Wolinsky, J. S.
    Truffinet, P.
    Bauer, D.
    Miller, A. E.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 84 - 84
  • [6] Efficacy of teriflunomide in MS patients with a primary presentation of optic neuritis: a subgroup analysis from the phase 3 TOPIC study
    Miller, A. E.
    Rog, D.
    Thangavelu, K.
    Truffinet, P.
    Cavalier, S.
    Wolinsky, J. S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 531 - 532
  • [7] Investigating the effect of teriflunomide on diffuse cortical grey matter volume loss in the phase 3 TOPIC study
    Sprenger, T.
    Lebrun-Frenay, C.
    Vermersch, P.
    Park, M. S.
    Chinchilla, D.
    McCombe, P.
    Lincoln, J.
    Bergsland, N.
    Dwyer, M.
    Kappos, L.
    Cavalier, S.
    Roesch, N.
    Guce, M.
    Poole, E.
    Zivadinov, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 864 - 864
  • [8] Investigating the Effect of Teriflunomide on Brain Volume Loss in the Phase 3 TOPIC Study
    Sprenger, Till
    Lebrun-Frenay, Christine
    Vermersch, Patrick
    Park, Min Su
    Chinchilla, Dennis
    McCombe, Pamela
    Lincoln, John
    Kappos, Ludwig
    Bergsland, Niels
    Dwyer, Michael
    Cavalier, Steven
    Roesch, Nora
    Somera-Molina, Kathleen
    Poole, Elizabeth
    Zivadinov, Robert
    NEUROLOGY, 2019, 92 (15)
  • [9] Efficacy and safety of teriflunomide in Chinese patients with relapsing forms of MS: A subgroup analysis of the phase 3 tower study
    Macdonell, R.
    Freedman, M.
    Xu, X.
    Vucic, S.
    Truffinet, P.
    Benamor, M.
    Thangavelu, K.
    Miller, A.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 135 - 135
  • [10] A Subgroup Analysis of the Phase 3 TOWER Study Assessing Efficacy and Safety of Teriflunomide in Asian Patients with Relapsing Forms of MS
    Macdonell, R.
    Freedman, M. S.
    Xu, X.
    Vucic, S.
    Truffinet, P.
    Benamor, M.
    Thangavelu, K.
    Miller, A. E.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (03) : 402 - 402
12345